Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis

Adam Maciejczyk, Jolanta Szelachowska, Bogdan Czapiga, Rafał Matkowski, Agnieszka Hałoń, B. Györffy, Paweł Surowiak

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BUBR1 (budding uninhibited by benzimidazole-related 1) represents the component of a controlling complex in mitosis. Defects in mitotic control complex result in chromosomal instability and, as a result, disturb the mitotic process. This study was aimed at examining the prognostic value linked to the expression of BUBR1 in a group of patients with breast cancer. We analyzed the expression of BUBR1 in 98 stage II breast cancer patients with a median follow-up of 15 years. Immunohistochemical reactions were performed using monoclonal antibodies against BUBR1. We also studied the prognostic value of BUBR1 mRNA expression using the Kaplan-Meier (KM) plotter, which assessed the effect of 22,277 genes on survival in 2422 breast cancer patients. A background database was established using gene expression data and survival information on 2422 patients downloaded from the Gene Expression Omnibus (GEO; Affymetrix HGU133A and HGU133+2 microarrays). The median relapse-free survival was 6.43 years. Univariate and multivariate analyses showed that higher expression of BUBR1 was typical for cases of shorter overall survival, disease-free time, and disease-specific survival. KM plotter analysis showed that elevated BUBR1 mRNA expression had a negative impact on patients' relapse-free, distant metastases-free, and overall survival. Elevated BUBR1 expression was associated with poor survival in early stage breast cancer patients.

Original languageEnglish
Pages (from-to)330-339
Number of pages10
JournalJournal of Histochemistry and Cytochemistry
Volume61
Issue number5
DOIs
Publication statusPublished - 2013

Fingerprint

Breast Neoplasms
Survival
Gene Expression
Recurrence
Chromosomal Instability
Messenger RNA
benzimidazole
Kaplan-Meier Estimate
Mitosis
Disease-Free Survival
Multivariate Analysis
Monoclonal Antibodies
Databases
Neoplasm Metastasis
Genes

Keywords

  • Breast cancer
  • BUBR1
  • Prognostic biomarker

ASJC Scopus subject areas

  • Anatomy
  • Histology
  • Medicine(all)

Cite this

Elevated BUBR1 expression is associated with poor survival in early breast cancer patients : 15-year follow-up analysis. / Maciejczyk, Adam; Szelachowska, Jolanta; Czapiga, Bogdan; Matkowski, Rafał; Hałoń, Agnieszka; Györffy, B.; Surowiak, Paweł.

In: Journal of Histochemistry and Cytochemistry, Vol. 61, No. 5, 2013, p. 330-339.

Research output: Contribution to journalArticle

Maciejczyk, Adam ; Szelachowska, Jolanta ; Czapiga, Bogdan ; Matkowski, Rafał ; Hałoń, Agnieszka ; Györffy, B. ; Surowiak, Paweł. / Elevated BUBR1 expression is associated with poor survival in early breast cancer patients : 15-year follow-up analysis. In: Journal of Histochemistry and Cytochemistry. 2013 ; Vol. 61, No. 5. pp. 330-339.
@article{502dfae526c34affb8599aefe4a74984,
title = "Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis",
abstract = "BUBR1 (budding uninhibited by benzimidazole-related 1) represents the component of a controlling complex in mitosis. Defects in mitotic control complex result in chromosomal instability and, as a result, disturb the mitotic process. This study was aimed at examining the prognostic value linked to the expression of BUBR1 in a group of patients with breast cancer. We analyzed the expression of BUBR1 in 98 stage II breast cancer patients with a median follow-up of 15 years. Immunohistochemical reactions were performed using monoclonal antibodies against BUBR1. We also studied the prognostic value of BUBR1 mRNA expression using the Kaplan-Meier (KM) plotter, which assessed the effect of 22,277 genes on survival in 2422 breast cancer patients. A background database was established using gene expression data and survival information on 2422 patients downloaded from the Gene Expression Omnibus (GEO; Affymetrix HGU133A and HGU133+2 microarrays). The median relapse-free survival was 6.43 years. Univariate and multivariate analyses showed that higher expression of BUBR1 was typical for cases of shorter overall survival, disease-free time, and disease-specific survival. KM plotter analysis showed that elevated BUBR1 mRNA expression had a negative impact on patients' relapse-free, distant metastases-free, and overall survival. Elevated BUBR1 expression was associated with poor survival in early stage breast cancer patients.",
keywords = "Breast cancer, BUBR1, Prognostic biomarker",
author = "Adam Maciejczyk and Jolanta Szelachowska and Bogdan Czapiga and Rafał Matkowski and Agnieszka Hałoń and B. Gy{\"o}rffy and Paweł Surowiak",
year = "2013",
doi = "10.1369/0022155413480148",
language = "English",
volume = "61",
pages = "330--339",
journal = "Journal of Histochemistry and Cytochemistry",
issn = "0022-1554",
publisher = "Histochemical Society Inc.",
number = "5",

}

TY - JOUR

T1 - Elevated BUBR1 expression is associated with poor survival in early breast cancer patients

T2 - 15-year follow-up analysis

AU - Maciejczyk, Adam

AU - Szelachowska, Jolanta

AU - Czapiga, Bogdan

AU - Matkowski, Rafał

AU - Hałoń, Agnieszka

AU - Györffy, B.

AU - Surowiak, Paweł

PY - 2013

Y1 - 2013

N2 - BUBR1 (budding uninhibited by benzimidazole-related 1) represents the component of a controlling complex in mitosis. Defects in mitotic control complex result in chromosomal instability and, as a result, disturb the mitotic process. This study was aimed at examining the prognostic value linked to the expression of BUBR1 in a group of patients with breast cancer. We analyzed the expression of BUBR1 in 98 stage II breast cancer patients with a median follow-up of 15 years. Immunohistochemical reactions were performed using monoclonal antibodies against BUBR1. We also studied the prognostic value of BUBR1 mRNA expression using the Kaplan-Meier (KM) plotter, which assessed the effect of 22,277 genes on survival in 2422 breast cancer patients. A background database was established using gene expression data and survival information on 2422 patients downloaded from the Gene Expression Omnibus (GEO; Affymetrix HGU133A and HGU133+2 microarrays). The median relapse-free survival was 6.43 years. Univariate and multivariate analyses showed that higher expression of BUBR1 was typical for cases of shorter overall survival, disease-free time, and disease-specific survival. KM plotter analysis showed that elevated BUBR1 mRNA expression had a negative impact on patients' relapse-free, distant metastases-free, and overall survival. Elevated BUBR1 expression was associated with poor survival in early stage breast cancer patients.

AB - BUBR1 (budding uninhibited by benzimidazole-related 1) represents the component of a controlling complex in mitosis. Defects in mitotic control complex result in chromosomal instability and, as a result, disturb the mitotic process. This study was aimed at examining the prognostic value linked to the expression of BUBR1 in a group of patients with breast cancer. We analyzed the expression of BUBR1 in 98 stage II breast cancer patients with a median follow-up of 15 years. Immunohistochemical reactions were performed using monoclonal antibodies against BUBR1. We also studied the prognostic value of BUBR1 mRNA expression using the Kaplan-Meier (KM) plotter, which assessed the effect of 22,277 genes on survival in 2422 breast cancer patients. A background database was established using gene expression data and survival information on 2422 patients downloaded from the Gene Expression Omnibus (GEO; Affymetrix HGU133A and HGU133+2 microarrays). The median relapse-free survival was 6.43 years. Univariate and multivariate analyses showed that higher expression of BUBR1 was typical for cases of shorter overall survival, disease-free time, and disease-specific survival. KM plotter analysis showed that elevated BUBR1 mRNA expression had a negative impact on patients' relapse-free, distant metastases-free, and overall survival. Elevated BUBR1 expression was associated with poor survival in early stage breast cancer patients.

KW - Breast cancer

KW - BUBR1

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=84879301920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879301920&partnerID=8YFLogxK

U2 - 10.1369/0022155413480148

DO - 10.1369/0022155413480148

M3 - Article

C2 - 23392733

AN - SCOPUS:84879301920

VL - 61

SP - 330

EP - 339

JO - Journal of Histochemistry and Cytochemistry

JF - Journal of Histochemistry and Cytochemistry

SN - 0022-1554

IS - 5

ER -